Pronova BioPharma reaches agreement with Apotex regarding Lovaza(TM) U.S. patent litigation
(Thomson Reuters ONE) -
Oslo, 30 March 2011: Pronova BioPharma announced today that it has entered into
an agreement with Apotex Corp. and Apotex Inc. (collectively "Apotex") to settle
patent litigation regarding Apotex's proposed generic version of Lovaza(TM)
(omega-3-acid ethyl esters) yesterday.
The settlement grants Apotex a license to enter the US market with a generic
version of Lovaza(TM) in the first quarter of 2015, or earlier depending on
certain circumstances.
The US District Court of Delaware will enter the Stipulation of Dismissal
without Prejudice and the corresponding patent litigation will be dismissed.
Other terms of the settlement are confidential.
Pronova BioPharma is currently still involved in lawsuits with Teva
Pharmaceuticals USA, Inc. ("Teva") and Par Pharmaceutical, Inc. ("Par"),
regarding infringement of the company's patents relating to Lovaza(TM).
- ends -
About Lovaza(TM)
Omacor(®)/Lovaza(TM) is the first commercialised product developed from Pronova
BioPharma's active pharmaceutical ingredient (API). It is also the first and
only EU and U.S. FDA-approved Omega 3-derived prescription drug. Blockbuster
status was achieved in the fourth quarter of 2009 as the global end-user sales
were USD 1 063 million. Pronova BioPharma estimates that more than one million
patients are currently on a prescription for one of the branded products
containing its API.
About Pronova BioPharma
Pronova BioPharma is a global leader in research, development and manufacture of
lipid therapies derived from nature
The group's first commercialised product is branded in a number of countries
throughout Europe, Asia and in the USA. End-user sales are growing rapidly in
all international markets and the reached annual run rate at 31 December 2010
was USD 1 260 million, according to IMS Health.
The product is the first and only EU- and FDA-approved Omega 3-derived
prescription drug.
Marketing and distribution of Pronova BioPharma's key product is currently
licensed to both local and global pharmaceutical companies.
Pronova BioPharma's headquarters are located at Lysaker in Norway, while
production takes place in manufacturing facilities at Sandefjord in Norway and
in Kalundborg, Denmark. The company's shares are listed on Oslo Børs with the
ticker code PRON.
For further information contact
Hamed Prodersen VP Investor Relations Tel:
+47 40 46 81 10
This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pronova BioPharma ASA via Thomson Reuters ONE
[HUG#1501508]
Unternehmensinformation / Kurzprofil:
Datum: 30.03.2011 - 08:12 Uhr
Sprache: Deutsch
News-ID 52938
Anzahl Zeichen: 3465
contact information:
Town:
Lysaker
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 226 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pronova BioPharma reaches agreement with Apotex regarding Lovaza(TM) U.S. patent litigation"
steht unter der journalistisch-redaktionellen Verantwortung von
Pronova BioPharma ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
